Roche will resume supplies of Pulmozyme to Russia

Swiss pharma giant Roche (ROG: SIX) will resume the supply of its cystic fibrosis drug Pulmozyme (dornase alfa), as the company has found the way for its imports to the Russian market, The Pharma Letter’s local correspondent reports.

Earlier, the Russian Ministry of Health recommended the company should work on the issue of importing the drug into Russia in foreign packaging. That became a response to numerous calls of Russian patients with cystic fibrosis on the government resolve the issue of availability of the original drug,

An official spokesman of Roche Russia - JSC Roche-Moscow- said in an interview with the Russian RBC business paper, the Swiss company continues to explore options to continue the supplies of Pulmozyme to Russia.